

In the Matter Of:

Purdue Pharma Bankruptcy

CECIL PICKETT, PH.D.

October 30, 2020



Highly Confidential Cecil Pickett, Ph.D. - October 30, 2020

176

1 CECIL PICKETT, PhD - HIGHLY CONFIDENTIAL
2 the family as to the extent of
3 distributions.

4 Q Do you recall a difference
5 in the discussions between a non-tax
6 distribution and a tax distribution?

7 A I'm sorry. Could you just
8 repeat that one more time, please?

9 Q Sure.

10 Do you remember a
11 difference in the discussions between
12 a non-tax distribution and a tax
13 distribution?

14 A Not to my recollection,
15 no.

16 Q Do you recall whether the
17 discussions about distributions were
18 had in connection with discussions
19 regarding the budget?

20 A Yes, I do recall that.

21 Q Okay.

22 And what is it that you do
23 recall about that?

24 A Well, the budget meetings
25 would -- would take place and there

Highly Confidential Cecil Pickett, Ph.D. - October 30, 2020

177

1 CECIL PICKETT, PhD - HIGHLY CONFIDENTIAL
2 was a sense of what kind of support
3 the activities needed with regard to
4 funding, and then I think the
5 distribution discussions came up after
6 that.

7 And so I think it was put
8 into context of what was -- what was
9 needed for funding of ongoing
10 activities -- or a request -- or
11 request from management.

12 I mentioned -- you know, I
13 mentioned the OTC business being
14 expanded. There was also a
15 geographical expansion in various
16 territories, too, that also needed
17 support in funding, particularly in
18 the Asian territories.

19 Q And so the support in
20 funding could have been at any of the
21 IACs, it would have been considered as
22 a whole?

23 A Would have -- I'm sorry --
24 (Simultaneous Crosstalk.)

25 MR. HERRINGTON: Objection